journal article·2023-09-13

Peritoneal Gene Transfection of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand for Tumor Surveillance and Prophylaxis

Nasha Qiu, Zhen Zhang, Xuyong Wei, Chang Xu, Xiaolong Jia, Kai Wang, Yunqi Chen, Shuai Wang, Renyi Su, Beini Cen, Youqing Shen, Chunying Chen, Yanpeng Liu, Xiao Xu

Nano Letters· Volume 23· Issue 17
Publisher page

Abstract

Peritoneal metastasis is very common in gastrointestinal, reproductive, and genitourinary tract cancers in late stages or postsurgery, causing poor prognosis, so effective and nontoxic prophylactic strategies against peritoneal metastasis are highly imperative. Herein, we demonstrate the first gene transfection as a nontoxic prophylaxis preventing peritoneal metastasis or operative metastatic dissemination. Lipopolyplexes of TNF-related-apoptosis-inducing-ligand (TRAIL) transfected peritonea and macrophages to express TRAIL for over 15 days. The expressed TRAIL selectively induced tumor cell apoptosis while exempting normal tissue, providing long-term tumor surveillance. Therefore, tumor cells inoculated in the pretransfected peritoneal cavity quickly underwent apoptosis and, thus, barely formed tumor nodules, significantly prolonging the mouse survival time compared with chemotherapy prophylaxis. Furthermore, lipopolyplex transfection showed no sign of toxicity. Therefore, this peritoneal TRAIL-transfection is an effective and safe prophylaxis, preventing peritoneal metastasis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Virus-based gene therapy research · Cancer Research and Treatments · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Center for Integrated Oncology and Precision Medicine, Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China

Zhejiang University School of Medicine, Hangzhou 310058, China

The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China

Zhejiang Key Laboratory of Smart Biomaterials and College of Chemical and Biological Engineering, Zhejiang Univeristy, Hangzhou 310027, China

CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100090, China

Zhejiang Longcharm Bio-tech Pharma Co., Ltd. Hangzhou 310027, China

Department of Urology, The First Affiliated Hospital of Ningbo University, Ningbo 315010, China

Funding

National Key Research and Development Program of China · Science and Technology Department of Zhejiang Province · National Natural Science Foundation of China

References (35)

Show source-provided references
1. 10.2214/AJR.10.503610.2214/AJR.10.5036 ↗
2. 10.1111/j.1440-1746.2009.05848.x10.1111/j.1440-1746.2009.05848.x ↗
3. 10.7150/jca.3739010.7150/jca.37390 ↗
4. 10.1038/nrclinonc.2010.4710.1038/nrclinonc.2010.47 ↗
5. 10.1038/nature0951510.1038/nature09515 ↗
6. 10.1016/j.lungcan.2016.03.00710.1016/j.lungcan.2016.03.007 ↗
7. 10.1200/JCO.2009.25.982010.1200/JCO.2009.25.9820 ↗
8. 10.1046/j.1432-0436.2002.700904.x10.1046/j.1432-0436.2002.700904.x ↗
9. 10.1007/s00018-017-2663-110.1007/s00018-017-2663-1 ↗
10. 10.1002/mco2.10010.1002/mco2.100 ↗
11. 10.1016/j.ygyno.2011.04.02110.1016/j.ygyno.2011.04.021 ↗
12. 10.1007/s10585-018-9896-810.1007/s10585-018-9896-8 ↗
13. 10.3390/cancers1318462610.3390/cancers13184626 ↗
14. 10.1038/nrclinonc.2009.21710.1038/nrclinonc.2009.217 ↗
15. 10.1186/s12885-019-6125-z10.1186/s12885-019-6125-z ↗
16. 10.1038/nm.289010.1038/nm.2890 ↗
17. 10.1038/nrc.2017.2810.1038/nrc.2017.28 ↗
18. 10.1002/adma.20160309510.1002/adma.201603095 ↗
19. 10.1002/adma.20200618910.1002/adma.202006189 ↗
20. 10.1016/S0169-409X(01)00216-210.1016/S0169-409X(01)00216-2 ↗
21. 10.1038/nrg376310.1038/nrg3763 ↗
22. 10.1021/acs.biomac.8b0044010.1021/acs.biomac.8b00440 ↗
23. 10.1080/0039791940801149610.1080/00397919408011496 ↗
24. 10.1002/EXP.2021008110.1002/EXP.20210081 ↗
25. 10.1002/EXP.2021013410.1002/EXP.20210134 ↗
26. 10.1016/j.cclet.2022.05.03210.1016/j.cclet.2022.05.032 ↗
27. Verstovsek S. · Cancer Res. · 1992 · 52 · 3880
28. 10.1016/j.ijbiomac.2010.02.00710.1016/j.ijbiomac.2010.02.007 ↗
29. 10.3389/fimmu.2016.0020410.3389/fimmu.2016.00204 ↗
30. 10.1091/mbc.e15-04-020910.1091/mbc.e15-04-0209 ↗
31. 10.1016/j.immuni.2005.05.00210.1016/j.immuni.2005.05.002 ↗
32. 10.1177/0091270992200796710.1177/00912709922007967 ↗
33. 10.1016/j.biomaterials.2010.07.05610.1016/j.biomaterials.2010.07.056 ↗
34. 10.1016/j.molimm.2007.04.00910.1016/j.molimm.2007.04.009 ↗
35. 10.1039/C8TX00005K10.1039/C8TX00005K ↗